Motif Bio (LSE: MTFB) is a late clinical stage antibiotic development company. It announced today that it has appointed Fulford Group Ltd, a specialist adviser to help in establishing commercial partnerships for iclaprim in territories outside the USA. It would be typical for such agreements to include upfront and milestone payments and ultimately royalties.
Zeus Capital Thoughts: “Having begun dosing patients in its two iclaprim phase III trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI), Motif is now better-placed, with Fulford’s assistance, to bring in a licensing partnership. Importantly, any early stage payments related to the deal would be non-dilutive. With the ongoing progress of the phase III programme, we expect Motif will grow in value and a licensing deal at this time for markets outside the USA would enable it to retain the highly valued rights to the product in the US market.”
Disclaimer: This research is intended for UK institutional investors only. It is not intended for retail customers and any retail customer should seek professional, independent advice before investing. For FCA purposes this marketing communication has not been prepared in accordance with legal requirements to promote the independence of investment research. Zeus Capital is not subject to any prohibition on dealing ahead of the dissemination of such investment research.
